Depression is associated with reduced levels of the monoamines in the brain, such as 5-HT. The selective 5-HT and noradrenaline re-uptake inhibitors (SNRIs) are thought to restore the levels of 5-HT and noradrenaline in the synaptic cleft by binding at their re-uptake transporters preventing the re-uptake and subsequent degradation of 5-HT and noradrenaline. This re-uptake blockade leads to the accumulation of monoamines in the synaptic cleft and the concentration returns to within the normal range. Selective 5-HT and noradrenaline re-uptake inhibitors have demonstrated clinical efficacy in the treatment of depression In the presence of the SNRIs, small amounts of 5-HT and noradrenaline continue to be degraded in the synaptic cleft.
Click here: Explore the use of SNRIs in depression treatment
Related content
Patients with bipolar disorder and comorbidities are typically more complex cases than those without medical or psychiatric comorbidities
Factors associated with mixed features includes unemployment among others
In this video, Professors Lakshmi Yatham, MD., and Christoph Correll, MD. discuss the challenges of differentiating bipolar disorder.